This announcement is a separate document:
アステラス製薬：抗体-薬物複合体 PADCEV（エンホルツマブ ベドチン） 中国で承認を取得
Astellas Pharma: PADCEV (Enfortumab vedotin), an Antibody-Drug Conjugate, has obtained approval in China.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.